Grufity logoGrufity logo

Charles River Laboratories International Inc Stock Research

CRL

193.56USD-1.34(-0.69%)Delayed

Market Summary

USD193.56-1.34
Delayed
-0.69%

CRL Alerts

CRL Stock Price

CRL RSI Chart

CRL Valuation

Market Cap

9.9B

Price/Earnings (Trailing)

20.28

Price/Sales (Trailing)

2.48

EV/EBITDA

12.51

Price/Free Cashflow

15.91

CRL Price/Sales (Trailing)

CRL Profitability

EBT Margin

15.67%

Return on Equity

16.34%

Return on Assets

6.4%

Free Cashflow Yield

6.28%

CRL Fundamentals

CRL Revenue

Revenue (TTM)

4.0B

Revenue Y/Y

21.52%

Revenue Q/Q

11.19%

CRL Earnings

Earnings (TTM)

486.2M

Earnings Y/Y

36.22%

Earnings Q/Q

94.26%

Price Action

52 Week Range

181.36308.15
(Low)(High)

Last 7 days

-10.9%

Last 30 days

-23.1%

Last 90 days

-10.8%

Trailing 12 Months

-24.8%

CRL Financial Health

Current Ratio

1.32

Debt/Equity

0.91

Debt/Cashflow

0.23

CRL Investor Care

Shares Dilution (1Y)

0.92%

Diluted EPS (TTM)

9.48

Peers (Alternatives to Charles River Laboratories International)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.4B
6.8B
-13.31% 3.22%
32.19
5.89
8.37% 3.64%
36.5B
14.4B
-15.87% -9.18%
33.43
2.53
3.86% 12.94%
35.5B
4.6B
5.65% -27.02%
-8.07
7.75
1.28% -677.95%
9.9B
4.0B
-23.12% -24.82%
20.28
2.48
12.31% 24.36%
MID-CAP
5.7B
1.5B
-22.25% 21.52%
23.09
3.88
27.80% 34.93%
3.5B
5.4B
-2.51% -56.11%
13.26
0.66
3.46% 13.48%
2.6B
278.3M
-26.82% -37.82%
-16.79
9.32
92.72% 15.56%
2.4B
509.7M
46.19% 25.15%
-16.73
4.74
5.24% -1628.17%
SMALL-CAP
744.4M
-
-10.86% -12.11%
-14.87
291.16
-34.21% -22.31%
271.1M
138.6M
-29.13% -76.08%
-8.07
1.96
32.30% -57.86%
224.8M
80.7M
-30.82% -43.30%
7.94
4.15
13.30% 130.72%
143.9M
60.3M
-71.28% -88.95%
-0.29
2.39
17.51% -38.93%
135.5M
65.0M
-20.46% -63.49%
-1.2
2.08
-23.92% -73.73%

Financials for Charles River Laboratories International

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue5.2%3,9763,7813,6883,6303,540
  S&GA Expenses9.1%665610574614620
EBITDA21.8%986809814--
EBITDA Margin13.0%0.25*0.22*0.22*--
Earnings Before Taxes29.6%623481---
EBT Margin20.2%0.16*0.13*0.13*--
Interest Expenses64.4%59.0036.0041.0054.0074.00
Net Income11.4%486436443422391
Net Income Margin6.0%0.12*0.12*0.12*0.12*-
Free Cahsflow0.9%620614656693-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets3.0%7,6037,3837,5297,0757,024
  Current Assets1.7%1,4391,4151,3931,3331,274
    Cash Equivalents20.8%234194200242241
  Inventory-2.2%256262257221199
  Goodwill2.7%2,8502,7762,8602162,712
Liabilities-2.8%4,5794,7114,8364,4044,432
  Current Liabilities7.6%1,0921,0141,0489941,033
  Long Term Debt-7.8%2,7082,9372,9972,6762,664
    LT Debt, Current-100.0%-0.000.000.00-
Shareholder's Equity13.3%2,9762,6272,6532,6152,535
  Retained Earnings12.0%1,4331,2801,1831,074981
  Additional Paid-In Capital1.4%1,8051,7811,7611,7451,718
Accumulated Depreciation-1,103----
Shares Outstanding0.1%51.0051.0051.0051.0050.00
Minority Interest-18.7%5.006.005.005.004.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations0.9%620614656693761
  Share Based Compensation4.1%74.0071.0071.0073.0071.00
Cashflow From Investing5.5%-607-643-905-1,397-1,437
Cashflow From Financing-241.6%-42.40-12.41218465673
  Buy Backs-0.3%39.0039.0039.0039.0041.00

Risks for CRL

What is the probability of a big loss on CRL?

45.8%


Probability that Charles River Laboratories International stock will be more than 20% underwater in next one year

41.1%


Probability that Charles River Laboratories International stock will be more than 30% underwater in next one year.

36.5%


Probability that Charles River Laboratories International stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Charles River Laboratories International was unfortunately bought at previous high price.

Drawdowns

Returns for CRL

Cumulative Returns on CRL

15.9%


10-Year Cumulative Returns

15.5%


7-Year Cumulative Returns

11.9%


5-Year Cumulative Returns

14.8%


3-Year Cumulative Returns

What are the long-term rolling returns for CRL?

FIve years rolling returns for Charles River Laboratories International.

Annualized Returns

Which funds bought or sold CRL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
16.08
75,550
347,550
0.01%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-0.73
1,401,960
15,552,000
0.02%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
58.65
31,985,200
74,256,200
0.08%
2023-03-08
Capital Asset Advisory Services LLC
reduced
-55.87
-281,469
320,531
0.03%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-19.68
-23,000
187,000
-%
2023-02-28
Voya Investment Management LLC
added
82.97
37,634,300
74,321,300
0.10%
2023-02-27
Parallax Volatility Advisers, L.P.
sold off
-100
-110,000
-
-%
2023-02-24
National Pension Service
unchanged
-
121,461
948,955
-%
2023-02-24
NATIXIS
sold off
-100
-6,030,000
-
-%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
2,405
24,405
-%

1–10 of 49

Latest Funds Activity

Are funds buying CRL calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CRL
No. of Funds

Charles River Laboratories International News

Nasdaq

Validea's Top Ten Healthcare Stocks Based On David Dreman - 3 ....

Nasdaq,
24 hours ago

PR Newswire

Schedule 13G FIlings of Charles River Laboratories International

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
11.71%
5,956,960
SC 13G/A
Jan 31, 2023
fmr llc
-
0
SC 13G/A
Jan 24, 2023
blackrock inc.
9.8%
4,981,145
SC 13G/A
Feb 09, 2022
vanguard group inc
11.63%
5,869,125
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Jan 28, 2022
blackrock inc.
10.1%
5,080,026
SC 13G/A
Feb 10, 2021
vanguard group inc
10.11%
5,027,904
SC 13G/A
Jan 27, 2021
blackrock inc.
10.8%
5,369,613
SC 13G/A
Jul 10, 2020
blackrock inc.
10.8%
5,341,383
SC 13G/A
Feb 12, 2020
vanguard group inc
10.89%
5,319,376
SC 13G/A

CRL Fair Value

Charles River Laboratories International fair value in different scenarios

The table shows the Fair Value estimates for Charles River Laboratories International for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

177.38

-8.36%

225.18

16.34%

309.56

59.93%

396.77

104.99%

458.30

136.77%
Current Inflation

162.60

-16.00%

203.18

4.97%

273.68

41.39%

346.61

79.07%

397.74

105.49%
Very High Inflation

144.43

-25.38%

176.72

-8.70%

231.55

19.63%

288.48

49.04%

328.06

69.49%

Historical Charles River Laboratories International Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Charles River Laboratories International

View All Filings
Date Filed Form Type Document
Mar 08, 2023
4
Insider Trading
Feb 24, 2023
4
Insider Trading
Feb 22, 2023
8-K
Current Report
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading

Latest Insider Trading transactions for CRL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-07
Girshick Birgit
gifted
-
-
-475
corporate executive vp & coo
2023-02-23
WALLMAN RICHARD F
bought
386,278
220
1,750
-
2023-02-22
Girshick Birgit
sold (taxes)
-75,028
243
-308
corporate executive vp & coo
2023-02-22
LaPlume Joseph W
sold (taxes)
-77,221
243
-317
evp, corp strategy & develop
2023-02-22
Knell Michael Gunnar
sold (taxes)
-12,423
243
-51.00
csvp&chief accounting officer
2023-02-22
Parisotto Shannon M
sold (taxes)
-33,129
243
-136
cevp, disc & safety assessment
2023-02-22
FOSTER JAMES C
sold (taxes)
-441,890
243
-1,814
chairman, president and ceo
2023-02-22
Barbo William D
sold (taxes)
-69,913
243
-287
corporate executive vp & cco
2023-02-22
Creamer Victoria L
sold (taxes)
-44,091
243
-181
evp & chief people officer
2023-02-16
Girshick Birgit
sold
-815,310
254
-3,205
corporate executive vp & coo

1–10 of 50

James C. Foster
20000
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CRL Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 25, 2021
Dec. 26, 2020
Total revenue$ 3,976,060$ 3,540,160$ 2,923,933
Costs and expenses:   
Selling, general and administrative665,098619,919528,935
Amortization of intangible assets146,578124,857111,877
Operating income650,975589,862432,729
Other income (expense):   
Interest income780652834
Interest expense(59,291)(73,910)(86,433)
Other income (expense), net30,523(35,894)99,984
Income before income taxes622,987480,710447,114
Provision for income taxes130,37981,87381,808
Net income492,608398,837365,306
Less: Net income attributable to noncontrolling interests6,3827,8551,002
Net income attributable to common shareholders$ 486,226$ 390,982$ 364,304
Earnings per common share   
Basic (in dollars per share)$ 9.57$ 7.77$ 7.35
Diluted (in dollars per share)$ 9.48$ 7.60$ 7.20
Weighted-average number of common shares outstanding:   
Basic (in shares)50,81250,29349,550
Diluted (in shares)51,30151,42550,611
Service   
Total revenue$ 3,216,904$ 2,755,579$ 2,296,156
Costs and expenses:   
Cost of services provided and products sold2,143,3181,837,4871,533,230
Product   
Total revenue759,156784,581627,777
Costs and expenses:   
Cost of services provided and products sold$ 370,091$ 368,035$ 317,162

CRL Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
shares in Thousands, $ in Thousands
Dec. 31, 2022
Dec. 25, 2021
Current assets:  
Cash and cash equivalents$ 233,912$ 241,214
Trade receivables and contract assets, net of allowances for credit losses of $11,278 and $7,180, respectively752,390642,881
Inventories255,809199,146
Prepaid assets89,34193,543
Other current assets107,58097,311
Total current assets1,439,0321,274,095
Property, plant and equipment, net1,465,6551,291,068
Venture capital and strategic equity investments311,602201,352
Operating lease right-of-use assets, net391,762292,941
Goodwill2,849,9032,711,881
Intangible assets, net955,2751,061,192
Deferred tax assets41,26240,226
Other assets148,279151,537
Total assets7,602,7707,024,292
Current liabilities:  
Accounts payable205,915198,130
Accrued compensation197,078246,119
Deferred revenue264,259219,703
Accrued liabilities219,758228,797
Other current liabilities204,575140,436
Total current liabilities1,091,5851,033,185
Long-term debt, net and finance leases2,707,5312,663,564
Operating lease right-of-use liabilities389,745252,972
Deferred tax liabilities215,582239,720
Other long-term liabilities174,822242,859
Total liabilities4,579,2654,432,300
Commitments and contingencies
Redeemable noncontrolling interest42,42753,010
Equity [Abstract]  
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock, $0.01 par value; 120,000 shares authorized; 50,944 shares issued and outstanding as of December 31, 2022 and 50,480 shares issued and outstanding as of December 25, 2021509505
Additional paid-in capital1,804,9401,718,304
Retained earnings1,432,901980,751
Treasury stock, at cost, zero shares as of December 31, 2022 and December 25, 202100
Accumulated other comprehensive loss(262,057)(164,740)
Total equity attributable to common shareholders2,976,2932,534,820
Noncontrolling interests (nonredeemable)4,7854,162
Total equity2,981,0782,538,982
Total liabilities, redeemable noncontrolling interests and equity$ 7,602,770$ 7,024,292
Beginning balance (in shares)00